[Interview] “Boehringer Ingelheim's return of 카지노 꽁머니 즉시지급877 technology marks a turnaround… Promising efficacy expected to achieve 'treatment' level”
[by Kang, In Hyo] “At this year’s JP Morgan Healthcare Conference, four companies, including Bristol Myers Squibb (BMS), Puretech, Pliant Therapeutics, and our company, presented their treatment pipelines for idiopathic pulmonary 카지노 꽁머니 즉시지급 (IPF). Based only on the data presented, I believe our data is the best.”
In an interview with <THE BIO during the ‘2025 JP Morgan Healthcare Conference,’ the world’s largest pharmaceutical and biotechnology investment event, held in San Francisco, USA, on January 15th (local time), James Jungkue Lee, CEO of Bridge Biotherapeutics, stated, “Although the global phase 2 clinical trial for our Idiopathic Pulmonary Fibrosis treatment candidate, ‘카지노 꽁머니 즉시지급877 (development code name),’ is still ongoing, the combined data from the treatment and placebo groups, which remain ‘unblinded,’ appear to be the most promising.”
“카지노 꽁머니 즉시지급877 is now in the final stages of global phase 2 clinical trials, with top-line data expected in April,” Lee further explained. “At that point, we will analyze the data separately from the treatment and placebo groups to determine the extent of change in the primary efficacy evaluation parameter, ‘Forced Vital Capacity (FVC),’ specifically in the treatment group alone.”
카지노 꽁머니 즉시지급 described Bridge Biotherapeutics’ official invitation to present during the main session of the JP Morgan Healthcare Conference as an unexpected and “big surprise.” The interview took place before the main session presentation scheduled for January 16.
“Had the multinational pharmaceutical company Boehringer Ingelheim not discontinued 카지노 꽁머니 즉시지급877, we could have secured global exclusivity,” Lee emphasized. “The development of 카지노 꽁머니 즉시지급877 is about two years ahead of its three competitors. At this JP Morgan Healthcare Conference, we held partnering discussions with four of the 10 major global pharmaceutical companies, and when including another, we have explored technology transfer opportunities for 카지노 꽁머니 즉시지급877 with a total of five global major companies,” he further commented. “Nine of the top 10 global pharmaceutical companies have expressed interest in 카지노 꽁머니 즉시지급877, and if the top-line results meet expectations, a global technology transfer could take place as early as June.”
“I was surprised to see seven attendees from the company we met with last Monday,” Lee particularly noted. “Their delegation included not only R&D staff but also commercialization staff, which clearly demonstrated the strong interest and significant demand from global companies for a large-scale technology transfer of 카지노 꽁머니 즉시지급877.”
In July 2019, Bridge Biotherapeutics entered into a technology transfer agreement with Boehringer Ingelheim for 카지노 꽁머니 즉시지급877 during its phase 1 clinical trial, valued at around KRW 1.5 trillion (approximately USD 1 billion). At the time, this represented the largest technology transfer deal for a single compound. In the same year, Bridge Biotherapeutics was listed on the KOSDAQ market, receiving KRW 60 billion in upfront payments and short-terms milestone fees (stage-by-stage technology fees) as part of the agreement. However, in 2020, Boehringer Ingelheim returned the rights of 카지노 꽁머니 즉시지급877 to Bridge Biotherapeutics, citing concerns over potential toxicity.
“I am deeply moved that the phase 2 clinical data is progressing well and that it has enabled us to present at the main session of the JP Morgan Healthcare Conference,” Lee remarked. “It was challenging when 카지노 꽁머니 즉시지급877, which had achieved a successful global technology export, was returned after just one year. However, our company’s position has strengthened since then, as the market for idiopathic pulmonary fibrosis treatments has grown and competitors have faced setbacks in their clinical trials.”
He went on to say, “카지노 꽁머니 즉시지급877 has demonstrated excellent safety, and if its efficacy meets expectations, it can be regarded as a true ‘treatment’,” and added, “To secure the best possible deal conditions, full-scale negotiations are expected to begin after the release of top-line data. We are committed to making the global technology transfer of 카지노 꽁머니 즉시지급877 a success once again.”
Lee concluded by stating, “Along with the global technology transfer of 카지노 꽁머니 즉시지급877, which is nearing the completion of phase 2 clinical trials this year, we plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the fourth quarter for phase 2 clinical trials of ‘카지노 꽁머니 즉시지급301,’ another pulmonary fibrosis drug candidate.” He added, “We also aim to finalize the phase 1 dose-escalation trial for ‘카지노 꽁머니 즉시지급207,’ a lung cancer treatment candidate, and proceed to phase 1b clinical trials.”
|
Bridge Biotherapeutic's treatment candidate for idiopathic pulmonary fibrosis, 카지노 꽁머니 즉시지급877 카지노 꽁머니 즉시지급877 is a first-in-class autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis. It works by selectively inhibiting 'autotaxin', a blood protein involved in inflammation and various types of fibrosis. Autotaxin is a protein composed of around 900 amino acids, acting as an enzyme that breaks down lysophosphatidylcholine (LPC) and converts it into lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA), a phospholipid produced by autotaxin, has been shown to bind to the LPA receptor and play a role in various signaling processes, including cell proliferation, prevention of cell death, cell movement, and the secretion of cytokines and chemokines. Pathologically, LPA is involved in inflammation and various forms of 카지노 꽁머니 즉시지급. |